TGFB1 and neoplasm: Therefore, the therapeutic benefit from inhibition of TGFβ has to be placed in the context of the other cellular signalling that would adversely affect an organism such as that observed experimentally in animal models of TGFβ deficiencies leading to increased tumour rate and autoimmune disorders [15], [16].